151 related articles for article (PubMed ID: 35301747)
1. 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study.
Ayele HT; Douros A; Filion KB
Br J Clin Pharmacol; 2022 Aug; 88(8):3771-3781. PubMed ID: 35301747
[TBL] [Abstract][Full Text] [Related]
2. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Benayoun S; Filion KB
Am J Med; 2023 Oct; 136(10):1000-1010.e7. PubMed ID: 37481022
[TBL] [Abstract][Full Text] [Related]
3. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Cabaussel J; Benayoun S; Filion KB
World J Urol; 2021 Jun; 39(6):2019-2028. PubMed ID: 32909173
[TBL] [Abstract][Full Text] [Related]
4. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
5. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Doherty N; Cardwell CR; Murchie P; Hill C; Azoulay L; Hicks B
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):428-434. PubMed ID: 36634196
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
9. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
Robinson D; Garmo H; Holmberg L; Stattin P
Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
[TBL] [Abstract][Full Text] [Related]
10. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
11. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
12. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
13. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang J; Latour CD; Olawore O; Pate V; Friedlander DF; Stürmer T; Jonsson Funk M; Jensen BC
JAMA Netw Open; 2023 Nov; 6(11):e2343299. PubMed ID: 37962887
[TBL] [Abstract][Full Text] [Related]
15. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
Lim SY; Laengvejkal P; Panikkath R; Nugent K
Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
[TBL] [Abstract][Full Text] [Related]
16. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
17. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
19. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
[TBL] [Abstract][Full Text] [Related]
20. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Persson R; Nickel JC; Jick SS
BMJ; 2016 Sep; 354():i4823. PubMed ID: 27659058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
